Clinical Case Reports (May 2022)

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab

  • Teresa Marta Cardesa‐Salzmann,
  • Bernhard Stephan,
  • Arne Simon,
  • Rhoikos Furtwängler,
  • Dominik Schöndorf,
  • Sabine Heine,
  • Eyad Torfah,
  • Margaux Lux,
  • Sonja Meyer,
  • Norbert Graf

DOI
https://doi.org/10.1002/ccr3.5902
Journal volume & issue
Vol. 10, no. 5
pp. n/a – n/a

Abstract

Read online

Abstract We report the case of a Jehovah's Witness adolescent patient with immune‐mediated thrombotic thrombocytopenic purpura after SARS‐Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patients for whom TPE is not an option might benefit from this approach.

Keywords